x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Pharma, SAI MedPartners

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma & Head of Strategy and Thought Leadership at SAI MedPartners, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and

science life sciences

All Episodes

00:45:52

IDEA Collider | Daphne Zohar

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/08/06

PureTech Health is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the “BIG” axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, the Company is

en

00:40:24

IDEA Collider | Pharma Book Club | Jane Metcalfe

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/07/23

25 Visions for the Future of Our Species We now have the tools to transform ourselves and our species. Greater health and longevity, enhanced brains, and engineered fertility are in the works. What’s just over the horizon is even more astonishing. We call this the neobiological frontier. The book is a collection of 25 essays, interviews, and works of fiction and art offering a big-picture perspective on the profound changes made possible by the merging of biology and technology. The book brings

en

00:57:40

IDEA Collider | Pharma Book Club | Thomas Hager

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/07/22

Chapter-by-chapter discussion, covering:opium/ heroinantibioticscontraceptive pillvaccinesand more...Find more by Thomas Hager here: https://www.thomashager.net

en

00:43:51

IDEA Collider | Pharma Book Club | Dr Jeremy Levin

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/06/23

Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA) Before Teva, Dr. Levin was member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity he was the

en

01:11:49

IDEA Collider | Pharma Book Club | Annie Duke

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/06/18

The books Annie recommends:Maria KonnikovaThe Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win Philip Tetlock, Dan GardnerSuperforecasting: The Art and Science of Prediction Don A MoorePerfectly Confident: How to Calibrate Your Decisions Wisely

en

00:55:37

IDEA Collider | Pharma Book Club | Peter Kolchinsky

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/06/14

Peter on Twitter: https://twitter.com/peterkolchinskyThe book's website: https://peterkolchinsky.com/bioLink to the Katherine Eban discussion:

en

00:48:33

IDEA Collider | Deborah Waterhouse

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/06/08

Deborah Waterhouse, CEO ViiV Healthcare Deborah was appointed to GSK’s Corporate Executive Team on 8th January 2020. She became Chief Executive Officer of ViiV Healthcare on 1st April 2017. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders. In this interview, we discuss cultures of innovation, innovation in the business model, purpose-driven innovation and more Deborah joined GSK in 1996 and was most recently the Senior Vice President of Primary Care

en

00:50:06

IDEA Collider | Melinda Richter

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/06/01

For more on JLABS, go to https://jlabs.jnjinnovation.com/JLABSNavigator#/As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a

en

00:49:43

IDEA Collider | Pharma Book Club | Clifton Leaf

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/05/22

In an archive recording, from 2015, the author of one of the best pharma-related books of the past decade, Clifton Leaf, gives us an insight into The Truth In Small Doses, Why We're Losing the War on Cancer-and How to Win It. (In this case, archive means that we thought we had lost the file, and then found it in a place we didn't expect!) Clifton, now Editor In Chief at Fortune Magazine, remains one of the most interesting voices in healthcare

en

00:57:57

IDEA Collider | Jack Scannell

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/04/07

Links to the papers we discussDiagnosing the Decline of Pharmaceutical R&D efficiency (2012): https://www.nature.com/articles/nrd3681When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis (2016): https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147215Pharmaceutical Evolution: Clinical Selection versus Intelligent Design: https://www.innogen.ac.uk/sites/default/files/2019-08/Innogen-Working-Paper-115.pdfJack can be contacted at

en

00:31:37

IDEA Collider | Pharma Book Club | Matt Ridley

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/03/10

Discussion of the new Matt Ridley book, How Innovation Works, published in May 2020. http://www.mattridley.co.uk Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, The Origins of Virtue, Genome, Nature via Nurture, Francis Crick, The Rational Optimist and The Evolution of Everything. His TED talk "When Ideas Have Sex" has been viewed more than two million times. He writes a weekly column in The Times

en

00:51:39

IDEA Collider | In conversation with Amrit Chaudhuri

IDEA Collider: Innovation & Asymmetric Learning in... ·

2020/02/19

Why Boston/ Cambridge and South San Francisco?Why not New York?Cultures of innovationThe new way, scaling start-upsCritical factors for biotech hubsEurope/ The UK and the rest of the worldWhere does innovation come from? How is it defined?

en

00:56:07

IDEA Collider | Vinayak K Prasad | Pharma Book Club

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/12/24

Interview with Vinayak K. Prasad, author of Malignant: How Bad Policy and Bad Evidence Harm People with Cancer An essential listen for anyone involved in cancer R&D. Vinay is one of the more interesting voices on Twitter (@VPrasadMDMPH), and the book presents a wonderful exploration of what's right with oncology R&D and what's wrong. The interview reveals how positively he sees the opportunity to refocus on what matters to oncologists, and more importantly, to patients. The book is published in

en

00:31:39

IDEA Collider | Jackie Hunter

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/12/04

IDEA Pharma: IDEA Collider Jackie Hunter https://www.youtube.com/watch?v=K59qefVIsbA Interviewer: So welcome to another series of IDEA Collider with leaders in innovation. I'm delighted to be joined by Jackie Hunter of Benevolent AI. First of all, would you like to tell us more about you and about Benevolent? Jackie Hunter: Yeah, I'm a board director of Benevolent AI. I've been with the company since 2016, where I came to set up the drop discovery and development arm of the business. It was

en

00:53:37

IDEA Collider | David Grainger

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/11/25

0:00 Defining innovation01:00 Incremental innovation vs big changes01:45 On designing back from the unmet need, and introducing innovation(Interruption by a phone call �)02:54 Problem backwards vs solution forwards03:55 On the ‘guided random walk’ and adoption of agility/ serendipity (low validity environments in pharma)04:45 Prediction, hubris and certainty in process06:50 The stopping rule in drug development (07:30 interruption by a phone call �)07:50 Zombie projects08:00 The ‘Keytruda story’ as

en

00:44:28

IDEA Collider | Joseph Owens, Google X

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/11/19

IDEA Pharma: IDEA Collider Mike Rea talks with Joseph Owens from Google X https://vimeo.com/269261531 Joseph Owens: Good to see you. Mike Rea: Thanks for coming over. So, this is just for the benefit of everyone who has seen the previous live streams with me talking [in the camera]. This is hopefully the start of a new series of live streams and recordings where we're going to interview people that I find most interesting among the folks that I come across. Joseph Owens: Well I hope you find some

en

01:04:42

IDEA Collider | In conversation with Nooman Haque

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/11/06

00:20 Introduction: what does Silicon Valley Bank's Life Sciences and Healthcare group do?01:00 Nooman's background01:30 How does SVB fit into the innovation ecosystem?02:00 Lending to companies who don't have products02:15 How does innovation happen: the myth of the lone inventor; the value of connections03:15 Parallels to non-pharma innovation models and ecosystems03:45: Innovation as the deployment into a market for the betterment of people and society04:10: Invention, innovation and diffusion of

en

00:49:32

IDEA Collider | Katherine Eban, author of Bottle of Lies

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/10/26

Mike Rea in conversation with Katherine Eban.Katherine's websiteThe book, on Amazon

en

00:43:10

IDEA Collider | Mene Pangalos, AstraZeneca

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/10/14

https://www.youtube.com/watch?v=AgUJQtQUrEs IDEA Pharma: A Conversation with Dr. Menelas Pangalos of AstraZeneca Mike Rea: Just a quick note this is Menelas Pangalos, can I have your official title? Dr. Menelas Pangalos: I am EVP of Innovative Medicines and early development. I’m at Biotech Unit and also Global Business Development. Mike Rea: Okay, we’ll get on to innovative medicines. This is obviously one of the series of Idea collider

en

00:54:04

IDEA Collider | John Carroll, Editor and Founder...

IDEA Collider: Innovation & Asymmetric Learning in... ·

2019/10/07

John Carroll can be found at:@johncendpts on Twitter orwww.endpts.com

en

61 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter